# To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

> **NCT07548411** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gritgen Therapeutics Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** GS1191-0445 injection

## Key facts

- **NCT ID:** NCT07548411
- **Lead sponsor:** Gritgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2024-12-31
- **Final completion:** 2029-12-23
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07548411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07548411, "To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07548411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*